

I. Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

Claims 1-14. (Cancelled)

Claim 15. (Currently Amended) A method of treating a mammal having metabolic abnormalities resulting from insulin resistance comprising administering an effective amount of a polymethoxyflavone composition comprising an effective ratio of sinesetin, nobiletin, nobiletin, tangeretin, heptamethoxyflavone and tetramethylscutellarein to reduce serum insulin levels by at least about 26%.

Claims 16-19. (Cancelled)

Claim 20. (Previously Presented) The method of claim 15 wherein said polymethoxyflavone composition is administered by a means chosen from oral, transdermal, rectal, intravenous, intramuscular, intraperitoneal, subcutaneous, topical, or by inhalation.

Claim 21. (Previously Presented) The method of claim 15 wherein said polymethoxyflavone composition is administered orally.

Claim 22. (Previously Presented) The method of claim 15, wherein said polymethoxyflavone is administered to said mammal in an amount of up to 5000 mg/day.

Claim 23. (Previously Presented) The method of claim 22 wherein said polymethoxyflavone is administered to said mammal in an amount of up to 70 mg/kg/day, based on the weight of said mammal.

Claims 24. (Cancelled)

Claim 25. (Currently Amended) The method of claim 15, wherein said polymethoxyflavone composition comprises about 9.3% sinesetin, about 35% nobiletin ~~nobiletin~~, about 11.1% tangeretin, about 33.5% heptamethoxyflavone and about 11.1% tetramethylscutellarein.

Claim 26. (Currently Amended) A method of treating a mammal having metabolic abnormalities resulting from insulin resistance comprising orally administering a solid or liquid composition ~~comprising~~ consisting essentially of an effective amount of a polymethoxyflavone composition consisting ~~essentially~~ of nobiletin ~~nobiletin~~ and tangeretin, wherein said polymethoxyflavone composition is administered in an amount of up to 5000 mg/day or up to 70 mg/kg/day based on the weight of said mammal, said composition reducing serum insulin levels by at least about 26%.

Claim 27. (New) A method of treating a mammal having metabolic abnormalities resulting from insulin resistance comprising orally administering a solid or liquid composition comprising an effective amount of a polymethoxyflavone composition consisting of nobiletin and tangeretin, wherein the polymethoxyflavone composition does not comprise any other polymethoxyflavones and wherein said polymethoxyflavone composition is administered in an amount of up to 5000 mg/day or up to 70 mg/kg/day based on the weight of said mammal, said composition reducing serum insulin levels by at least about 26%.

Claim 28. (New) The method of claim 15, wherein said polymethoxyflavone composition consists essentially of about 9.3% sinesetin, about 35% nobiletin, about 11.1% tangeretin, about 33.5% heptamethoxyflavone and about 11.1% tetramethylscutellarein.

Claim 29. (New) The method of claim 15, wherein said polymethoxyflavone composition does not comprise any other polymethoxyflavones.